


L-5-Hydroxytryptophan

Cat. No.:	HY-B1716		
CAS No.:	4350-09-8		
Molecular Formula:	C ₁₁ H ₁₂ N ₂ O ₃		
Molecular Weight:	220.22		
Target:	Endogenous Metabolite		
Pathway:	Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (454.09 mM; Need ultrasonic)				
	Preparing Stock Solutions	Solvent Concentration	1 mg	5 mg	10 mg
		1 mM	4.5409 mL	22.7046 mL	45.4091 mL
		5 mM	0.9082 mL	4.5409 mL	9.0818 mL
		10 mM	0.4541 mL	2.2705 mL	4.5409 mL
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (11.35 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (11.35 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	L-5-Hydroxytryptophan (L-5-HTP), a naturally occurring amino acid and a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, is the immediate precursor of the neurotransmitter serotonin and a reserpine antagonist ^[1] . L-5-Hydroxytryptophan (L-5-HTP) is used to treat fibromyalgia, myoclonus, migraine, and cerebellar ataxia ^{[2][3][4][5]} .
IC ₅₀ & Target	Human Endogenous Metabolite

REFERENCES

- [1]. ARVID CARLSSON, et al. 3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists. *Nature* 180, page1200 (1957).
- [2]. Caruso I, et al. Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome. *J Int Med Res.* 1990 May-Jun;18(3):201-9.
- [3]. Thal LJ, et al. Treatment of myoclonus with L-5-hydroxytryptophan and carbidopa: clinical, electrophysiological, and biochemical observations. *Ann Neurol.* 1980 Jun;7(6):570-6.
- [4]. Boiardi A, et al. 5-OH-Tryptophane in migraine: clinical and neurophysiological considerations. *J Neurol.* 1981;225(1):41-6.
- [5]. Trouillas P, et al. Improvement of cerebellar ataxia with levorotatory form of 5-hydroxytryptophan. A double-blind study with quantified data processing. *Arch Neurol.* 1988 Nov;45(11):1217-22.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA